The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...
The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.
The letter focuses exclusively on manufacturing control strategies for the biological component and contract manufacturing facility deficiencies. The Food and Drug Administration (FDA) has issued a ...
Lumvoa (veligrotug-vvze) is now FDA-approved to treat thyroid eye disease regardless of activity or duration, offering a new therapeutic option for both active and chronic phases. The Food and Drug ...
For ifosfamide, used to treat sarcomas, lymphomas and testicular cancers, some doctors are already meeting to decide who gets treated.
The total costs of dementia are anticipated to be $818 billion in 2026, driven by quality-of-life losses for persons with dementia and care partners, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results